Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.40 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728573 | 0.81 | KDM4E (0.53) | TGFBR1KDM4E | |
| SCHEMBL461050 | 0.79 | FLT3 (0.44) | IRAK4EPHB3TGFBR1L3MBTL1KDM4E | |
| SCHEMBL461457 | 0.77 | TGFBR1 (0.42) | IRAK4TGFBR1L3MBTL1KDM4E | |
| SCHEMBL359281 | 0.76 | TYK2 (0.53) | IRAK4TGFBR1L3MBTL1KDM4E | |
| SCHEMBL405711 | 0.76 | JAK2 (0.48) | TGFBR1 | |
| SCHEMBL23744412 | 0.73 | JAK2 (0.41) | IRAK4TGFBR1L3MBTL1 | |
| SCHEMBL28650156 | 0.73 | FGFR4 (0.44) | IRAK4TGFBR1L3MBTL1KDM4E | |
| SCHEMBL23728537 | 0.72 | TGFBR1 (0.39) | IRAK4TGFBR1L3MBTL1KDM4E | |
| SCHEMBL18208833 | 0.72 | SMPD3 (0.62) | IRAK4EPHB3TGFBR1KDM4ECCNT1 | |
| SCHEMBL18208666 | 0.72 | JAK2 (0.50) | IRAK4TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885EPHB3 1710/4885TGFBR1 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.